Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | HTR2A | P28223 | 6/20 | 0.45 |
| ▸ | HTR2C | P28335 | 6/20 | 0.45 |
| ▸ | HTR2B | P41595 | 6/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461946 | 0.87 | HTR2A (0.54) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL7545824 | 0.85 | HTR2A (0.53) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL16397357 | 0.79 | SIGMAR1 (0.43) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL2766554 | 0.79 | HTR2A (0.50) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL29723594 | 0.79 | HTR2A (0.50) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL7932553 | 0.78 | SIGMAR1 (0.53) | SIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL2786789 | 0.77 | HTR2A (0.49) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL29613747 | 0.77 | HTR2C (0.42) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL7993604 | 0.77 | SIGMAR1 (0.41) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL8244197 | 0.77 | HTR2A (0.39) | SIGMAR1HTR2AHTR2CHTR2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681209-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8765953-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-1888562-B1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARM HOLDING (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8530453-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20110257222-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | AQUILUS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. | 2011-09-22 | — | — | US | disclosed |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-1843820-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | Alantos Pharmaceuticals, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2006116157-A9 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS INC (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006128184-A2 | PYRIMIDINE OR TRIAZINE FUSED BICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS-PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270701-A1 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006083454-A1 | MULTICYCLIC BIS-AMIDE MMP INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | ALANTOS PHARMACEUTICALS, INC., | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | SIGMAR1 4742/4885HTR2A 1675/4885HTR2C 1853/4885 |
| US-20060293345-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, MMP10 | SIGMAR1 3887/4885HTR2A 2553/4885HTR2C 2163/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | SIGMAR1 3986/4885HTR2A 2443/4885HTR2C 1552/4885 |
| US-20060173183-A1 | Multicyclic bis-amide MMP inhibitors | MMP13, MMP3, MMP11 | SIGMAR1 3114/4885HTR2A 1219/4885HTR2C 1325/4885 |
| US-20060270701-A1 | Dipeptidyl peptidase-IV inhibitors | DPP4, DPP3, DPP7 | SIGMAR1 4353/4885HTR2A 1763/4885HTR2C 1317/4885 |
| US-20110257222-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | MMP3, MMP9, MMP10 | SIGMAR1 1060/4885HTR2A 1027/4885HTR2C 703/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | SIGMAR1 3986/4885HTR2A 2443/4885HTR2C 1552/4885 |
| US-20110230452-A1 | Compounds and methods for the treatment of pain and other diseases | MMP9, MMP10, MMP3 | SIGMAR1 694/4885HTR2A 250/4885HTR2C 272/4885 |
| US-20110112051-A1 | Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP7 | SIGMAR1 4353/4885HTR2A 1763/4885HTR2C 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.